Proteome Editing Through Molecular Glue Degraders Innovating Beyond New Heights | January 2025 Forward-Looking Statements This communication includes express and implied "forward-looking statements," including forward-looking statements within the meaning of the Private Securities Littleation Reforical frances naticals oncernes include all statements that are not thistorical facts and, in same cases can be identified op terms such as may Reforio for 1995. Forw "will " "ongoing," or the negative of these ter ...

Initial clinical data from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader (MGD) MRT-6160 expected in Q1 2025 Additional clinical results from Phase 1/2 study of MRT-2359 in MYC-driven solid tumors, including biomarker and activity data, anticipated in Q1 2025 MRT-8102, a NEK7-directed MGD targeting diseases driven by IL-1β and the NLRP3 inflammasome, on track for IND filing in H1 2025 Year-end cash and equivalents expected to be $377 million as of December 31, 2024 (unaudited) and anticipate ...

BOSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 5:15 p.m. PST. A webcast of the presentation will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com, an ...

BOSTON, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Eric A. Hughes, M.D, Ph.D., to its Board of Directors. Dr. Hughes is currently Executive Vice President, Global R&D and Chief Medical Officer of Teva Pharmaceuticals and brings decades of biopharmaceutical industry leadership experience to Monte Rosa. “I am very excited to welcome Dr. ...

Shares of Monte Rosa Therapeutics (GLUE) have gained 16.4% over the past four weeks to close the last trading session at $10.36, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $17 indicates a potential upside of 64.1%.The mean estimate comprises six short-term price targets with a standard deviation of $2.45. While the lowest estimate of $15 indicates a 44.8% increase from the ...

Shares of Monte Rosa Therapeutics (GLUE) have gained 54.5% over the past four weeks to close the last trading session at $8.48, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $17 indicates a potential upside of 100.5%.The average comprises six short-term price targets ranging from a low of $15 to a high of $20, with a standard deviation of $2.45. While the lowest estimate indic ...

Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.70 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 35.56%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.50 per share when it actually produced a loss of $0.43, delivering a surprise of 14%.Over the last four quarters, t ...

亏损情况 - 2023年12月31日止年度净亏损1.354亿美元2022年为1.085亿美元[60] - 2024年9月30日止九个月净亏损8610万美元2023年为1.021亿美元[60] - 截至2024年9月30日累计赤字4.52亿美元现金等为2.471亿美元[60] - 2024年9月30日止三个月净亏损2385.9万美元2023年为3488.4万美元[67] - 2024年前九个月净亏损为8613.7万美元较2023年减少1596.3万美元[74] 特定时期收支情况 - 2024年9月30日止三个月合作收入921.6万美元[67] - 2024年9月30日止三个月研发费用2761.6万美元2023年为2830.6万美元[67] - 2024年9月30日止三个月一般及行政费用812.7万美元2023年为866.2万美元[67] - 2024年前九个月合作收入为1500万美元[74] - 2024年前九个月研发费用为8269.7万美元较2023年减少144万美元[74] - 2024年前九个月一般及行政费用为2639.4万美元较2023年增加208.3万美元[74] - 2024年前九个月其他收入为838.5万美元较2023年增加167.7万美元[77] - 2024年前九个月经营活动现金净流出8692.6万美元[83] - 2024年前九个月投资活动现金净流出1355.6万美元[83] - 2024年前九个月融资活动现金净流入9828.4万美元[83] 员工数量 - 截至2024年9月30日研发员工105名2023年为107名[69] - 截至2024年9月30日一般及行政员工28名2023年为26名[71] 研发费用预期 - 公司预计研发费用在可预见未来将大幅增加[64] 资金可支撑运营情况 - 基于当前运营计划及诺华1.5亿美元预付款公司现有资金可满足至少未来12个月运营及资本支出需求[87] - 公司将继续通过股权融资债务融资或其他资本来源满足资金需求[87] 财务报表编制依据 - 公司依据美国通用会计准则编制未经审计的中期简明合并财务报表[89] 公司收入相关情况 - 公司收入主要与罗氏的许可和合作协议相关并按ASC 606进行会计处理[90] - 确定ASC 606范围内安排的收入时需进行五步操作[90] - 交易价格含可变对价时需估计应计入的金额[92] - 单一履约义务则将整个交易价格分配给该义务[92] - 多个履约义务需按相对单独售价分配交易价格[92] - 公司利用判断评估履约义务性质确定收入确认方式[92] - 每个包含研发或监管里程碑付款安排开始时进行评估[92] - 报告期末重新评估交易价格和预计总成本[92] 会计准则采用情况 - 自2012年4月起公司为新兴成长公司可延迟采用某些会计准则[97]

财务收支情况 - 2024年第三季度合作收入为920万美元2023年同期无合作收入[11] - 2024年第三季度研发费用为2760万美元2023年同期为2830万美元[12] - 2024年第三季度一般及行政费用为810万美元2023年同期为870万美元[13] - 2024年第三季度净亏损为2390万美元第二季度为3030万美元[13] - 截至2024年9月30日现金等为2.471亿美元[14] - 2024年前三季度合作收入为14,975美元2023年同期无[23] - 2024年前三季度研发费用为82,697美元2023年同期为84,137美元[23] - 2024年前三季度净亏损为86,137美元2023年同期为102,100美元[23] - 截至2024年9月30日现金及现金等价物为125,575美元 2023年12月31日为128,101美元[22] 与诺华合作相关 - 诺华将支付1.5亿美元预付款蒙特罗莎有资格获得高达21亿美元的里程碑付款[1][4] 基于现有资金的运营情况 - 基于现有资金和诺华预付款预计可支撑运营至2028年[15] 临床研究进展 - MRT - 6160一期临床研究正在进行预计2025年第一季度获得初步临床数据[1] - MRT - 2359一期/二期临床研究正在进行预计2024年底前公布相关数据[3][8] - MRT - 8102预计2025年上半年提交IND申请[1][5] - 预计2024年底披露MRT - 2359一期/二期研究一期剂量递增部分的安全、生物标记物和临床活动数据[20] - 预计2024年底确定并披露MRT - 2359的二期推荐剂量[20] - 预计2024年底给出二期扩展队列启动的指导[20] - 预计2025年上半年向FDA提交MRT - 8102的IND[20] 每股净亏损与加权平均流通股数 - 2024年前三季度基本和稀释后每股净亏损为1.21美元2023年同期为2.06美元[23] - 2024年前三季度加权平均流通股数为71,173,647股2023年同期为49,533,143股[23]

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for moment ...